Backlight Announces New Organizational Structure with Two Divisions: Backlight Creative and Backlight Streaming
Backlight, a global media technology company that dramatically improves every stage of the video and entertainment content lifecycle, today announced a new organizational structure featuring two new divisions: Backlight Creative and Backlight Streaming. Backlight Creative includes the customers, products and teams from ftrack, iconik and Celtx, while Backlight Streaming includes the same from Zype and Wildmoka.
Since acquiring multiple fast-growing media technology brands starting in 2021, Backlight has operated as a holding company with each acquisition largely being run as independent business units. Backlight’s new divisional structure aligns complementary teams and products around shared target markets, media workflows and customers, with the goal of driving innovation, customer success and continued growth.
“This new divisional org structure will enable Backlight to better serve our rapidly growing customer base with larger, aligned teams and differentiated, integrated solutions,” said Ben Kaplan, president and CEO of Backlight. “The complementary nature and strategic synergies of our different acquisitions were central to Backlight’s original strategy and have been proven out over the past 18 months. The entire Backlight team is excited about the value that this new organizational structure will drive for our customers.”
Backlight Creative provides award-winning creative collaboration software including secure and efficient media management, production tracking, and integrated review and approval tools. Creative and video teams in film, TV, gaming, agencies and their clients rely on Backlight Creative’s iconik, ftrack and Celtx product lines to streamline creative workflows and deliver their visions accurately, on time and on budget.
Media technology veteran Mike Green has been named the Divisional CEO of Backlight Creative after serving as Backlight’s Chief Growth Officer since September 2021. Prior to joining Backlight, Green held executive strategy, marketing and corporate development positions at Brightcove, as well as executive and management positions at Comcast, Collecta and Kaboose (now Disney). Green holds degrees from Brown University and Columbia Business School.
Backlight Streaming delivers leading cloud-native solutions for OTT streaming, video management, clip creation, hyper-distribution, and monetization from its Zype and Wildmoka product lines. Leading media publishers, content providers and broadcasters rely on Backlight Streaming’s full stack software solutions to ingest, transform, manage, distribute, and monetize live and on-demand video to connect content owners to all marketplaces globally.
Ed Laczynski and Cristian Livadiotti, both co-founders and CEOs of Zype and Wildmoka respectively, are now Divisional co-CEOs of Backlight Streaming. The two CEOs have a fundamental understanding of what the Zype and Wildmoka product lines can do together, while remaining completely modular, complementary and flexible. Both Laczynski and Livadiotti co-founded and led their companies prior to their acquisitions by Backlight in 2021.
Laczynski has more than 20 years of technology leadership experience having worked with companies like IPG/McCann-Erickson, and Datapipe (now Rackspace). Laczynski holds a degree from New York University. Livadiotti has 20 years of experience in the media and telecom domains, setting up ventures, projects and organizations both in startups and large multinationals environments. He holds degrees from École Polytechnique and Télécom Paris.
About Backlight
Backlight is a global media technology company that dramatically improves every stage of the video and entertainment content lifecycle - from creation through monetization. Backed by $200M in funding from PSG, Backlight has acquired six leading media software companies since launching in 2021. Video-forward organizations solve their mission-critical business and operational challenges by partnering with Backlight’s two divisions: Backlight Creative and Backlight Streaming. Backlight Creative provides award-winning software solutions for secure and efficient media management, production tracking and creative collaboration including iconik, ftrack and Celtx. Backlight Streaming delivers leading cloud-native solutions for OTT streaming, hyper-distribution and monetization from Zype and Wildmoka. For more information visit backlight.co.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005524/en/
Contact information
Kiní Schoop
VP, Corporate Communications
media@backlight.co
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom